Please login to the form below

Not currently logged in
Email:
Password:

Novo’s diabetes pill defeats Merck’s Januvia in trial

Oral semaglutide also outshines its best-selling diabetes injectable Victoza

Novo

Novo Nordisk’s oral semaglutide is gearing up to be quite the game changer for the GLP-1 class - which has long been dominated with injectables - and has been boosted by new results from its PIONEER programme.

Comparing oral semaglutide to Merck & Co’s DPP-4 inhibitor Januvia (sitagliptin), PIONEER 7 investigated the efficacy and safety of the GLP-1 inhibitor in people with type 2 diabetes.

The trial specifically targeted a reduction in HbA1c -  blood sugar levels - and oral semaglutide demonstrated that from a baseline HbA1c of 8.3%, 63% of people treated with Novo’s drug achieved the target HbA1c level – 7% or lower – compared to 28% of those treated with sitagliptin after 52 weeks of treatment.

Novo’s chief scientist officer Mads Krogsgaard Thomsen said: “With significant one-year results in a real-world dose setting, oral semaglutide was superior to sitagliptin by documenting a greater proportion of people achieving the HbA1c target level.”

The drug also hit the mark in the obesity setting, with patients achieving statistically significant and superior reductions in body weight versus sitagliptin.

A familiar story was told when oral semaglutide was compared with Novo’s best-selling diabetes blockbuster Victoza (liraglutide).

PIONEER 4 saw the enrolment of 711 people with type 2 diabetes inadequately controlled on metformin, or without an SGLT-2 inhibitor.

Like PIONEER 7, PIONEER 4 achieved its primary objective demonstrating a non-inferior reduction in HbA1c compared to Victoza (1.3% and 1.2% vs 1.1% and 0.9%) for weeks 26 and 52 respectively.

Reductions in body weight from a baseline was also reported at 26 and 52 weeks, and that trial compared oral semaglutide to both Victoza and placebo.

Patients achieved a 4.7 and 5.0kg loss compared to 3.2 and 3.1kg with Victoza and 0.7 and 1.2kg with placebo.

Novo is already a big player in the diabetes setting, with Victoza still gaining ground despite strong competition from Eli Lilly’s GLP-1 Trulicity (dulaglutide).

It could help Novo greatly expand its share of the diabetes market if the once-daily tablet gains approval, with its oral formulation helping it to be the first GLP-1 to bypass patients' reluctance to use needles.

Article by
Gemma Jones

21st June 2018

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
certain health

Transforming the way health brands and companies communicate, we deliver creative science led, insight-driven solutions that give award winning results...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....